UCB races to regulators after $2.5B rare disease bet delivers data for attack on AstraZeneca and argenx Pfizer's $130M Lyme disease vaccine advances to phase 3 after 3rd shot shown to increase antibodies Arcellx raises $124M in Wall Street debut to bankroll study of multiple myeloma CAR-T Sponsored: Taking a Different Approach to Drug Development Arrowhead ‘changing horses’ for ENaC pulmonary program as phase 1/2 asset shelved Sponsored: Choose wisely. Biospecimens can make or break your biomarker-driven cancer research Unity once again lays off large number of staff, narrows focus to ophthalmology assets Synaffix lines up $586M pact with MacroGenics en route to 'one-stop shop' for ADC tech In Roche's rosy pandemic scenario, it will take a $2B hit to COVID sales this year Quest CEO Rusckowski to step down after a decade, following record-setting 2021 Sanofi's Dupixent rolls on, but US flu shots took backseat to COVID-19 boosters in the fourth quarter Labcorp launches online platform for ordering at-home tests, scheduling in-person appointments Remote possibilities: United BioSource teams with Seqster to boost decentralized study offering From Amazon to New Balance, consumer brand execs bring 'outsider' perspective to healthcare Fierce Pharma Asia—AstraZeneca China's fraud investigation; Women promoted at Takeda; Samsung buy of Biogen's stake in biosimilar JV Chutes & Ladders—Pfizer poaches Roche's early R&D leader Pao to replace development chief Featured Story | By Nick Paul Taylor UCB’s $2.5 billion gamble on Ra Pharmaceuticals has yielded positive phase 3 data. With the rare disease clinical trial hitting its primary endpoint, UCB is preparing to file to join AstraZeneca and argenx in an increasingly congested space. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Pfizer is taking its Valneva-partnered Lyme disease vaccine into phase 3. With midphase data supporting a three-dose series, the allies plan to kick off a phase 3 clinical trial of the regimen in the third quarter. read more By Kyle LaHucik Cell therapy biotech Arcellx raised $124 million in its Wall Street debut, at the low end of its proposed range, to bankroll a phase 2 CAR-T BCMA therapy trial in patients with multiple myeloma, expected to start by year's end. If the study is successful, the company hopes to file the cell therapy with the FDA for approval. read more Sponsored by: TD2 Dive into the unique history of TD2 and learn how their approach to cancer drug development impacts clinical and partner success. read more By Annalee Armstrong Arrowhead Pharmaceuticals is ditching a pulmonary drug after it failed to hit the mark in a phase 1/2 cystic fibrosis trial last year. But the biotech is filling up its quiver with at least two more prospects in the program as a replacement. read more Sponsored by: Precision for Medicine Advances in cancer biomarker discovery, validation and clinical applications hinge on one critical resource: Quality biospecimens. Optimize and accelerate program success by sourcing and selecting the right samples. read more By Kyle LaHucik Unity Biotechnology is laying off about half of its staff and focusing its pipeline only on ophthalmology assets so it can extend cash runway into early 2023 to bankroll multiple midstage eye disease trials this year. The California biotech laid off 30% of its workforce in fall 2020 after a previous blunder with a knee pain drug. read more By Kyle LaHucik Add cancer-focused biotech MacroGenics to the list of biopharmas shoveling out cash for Synaffix's antibody-drug conjugate technology. The Maryland biotech will dish out up to $586 million for access to Synaffix's ADCs for three programs. read more By Tracy Staton Roche's COVID sales will be more than $2 billion lighter in 2022, execs said Thursday, but that assumes omicron burns out, vaccines keep working and immunity lasts for years. Reality may be quite different. read more By Andrea Park Rusckowski will be succeeded as president and CEO by James Davis, currently the executive vice president of the company’s general diagnostics business. read more By Fraiser Kansteiner Sanofi reported a strong fourth quarter everywhere except in U.S. flu vaccine sales, where the company took a 48% sales hit. It blamed the slump on prioritization of COVID-19 boosters in November and December, and the company expects an influenza rebound in 2022. read more By Andrea Park Building on the success of its direct-to-consumer COVID-19 testing options, Labcorp is supplanting its Pixel brand with a new platform that allows it to sidestep healthcare provider middlemen and enable individuals to order their own diagnostic tests. read more By Gareth Macdonald Decentralized trials are here to stay, says United BioSource, which has partnered with “patient centric” healthcare tech firm Seqster PDM to bolster its remote study business. read more By Anastassia Gliadkovskaya Wellforce recently appointed its first ever chief consumer officer. The move comes amid a rising trend in healthcare: executives sourced from outside the industry, and in particular from consumer brands, to lead innovation strategies. read more By Kevin Dunleavy Employees at AstraZeneca China are under investigation for insurance fraud. Takeda has promoted several women to key positions. Samsung has bought out Biogen’s stake in its biosimilar-focused Samsung Bioepis joint venture for $2.3 billion. And more. read more By Kyle LaHucik Pfizer picks from Roche's executive team, snagging pharma early R&D leader William Pao as the Big Pharma's next chief development officer. Leo Pharma poaches from ... a Danish meme stock for its new CEO, who will lead a reorganization of the dermatology biopharma. And Sio Gene Therapies CEO Cheruvu is out the door as Parkinson's program also hits the exit. read more Resources Sponsored by: Blue Matter, strategic consultants in the life sciences What’s in store for the CNS therapeutics market in 2022? This paper looks ahead in Alzheimer’s, Parkinson’s, DMD, psychiatric disorders, pain, and more. Sponsored by: Thermo Fisher Scientific Learn how a CDMO partnered with Thermo Fisher Scientific to manage high-volume process liquid and buffer preparation scale-up. Download the free case study from Thermo Fisher Scientific Sponsored by: Thermo Fisher Scientific A variety of genetic analysis methods are valuable in ensuring that ex vivo human cells to be used for cell-based therapies are correctly identified, have the correct characteristics, and are free of contaminants. Sponsored by: IQVIA Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making. Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Fierce Drug Safety Summit March 8-9, 2022 | Virtual Fierce BD&L Summit for Life Sciences March 15-16, 2022 | San Francisco, CA Fierce Promotional Review Committee Compliance and Best Practices Summit April 12-14, 2022 | New Brunswick, NJ Fierce Medical Affairs Strategic Summit (MASS) East April 12-14, 2022 | New Brunswick, NJ Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Leaders in Life Sciences Forum May 16-17, 2022 | Virtual Event Fierce Health IT Summit May 24, 2022 | Virtual Event Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Pharma PR & Communications Summit West June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce Biotech Next-Gen Week June 29-30, 2022 | Virtual Event Fierce Pharma PR & Communications Summit July 2022 | Location TBD (NYC Metro Area) Fierce MedTech Summit August 8-9, 2022 | Minneapolis, MN Promotional Review Committee Compliance and Best Practices Summit West (PRC West) September 2022 | San Diego, CA Medical Affairs Strategic Summit (MASS West) September 2022 | San Diego, CA Fierce Biotech Summit October 10-11, 2022 | Location TBD Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Pharma Marketing Awards October 19, 2022 | Philadelphia, PA Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Virtual Event Fierce European Trial Master File Summit October 31- November 2, 2022 | London Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce Diversity, Equity & Inclusion Forum November 15-16, 2022 | Virtual Event Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Boston, MA Fierce New Product Planning Summit November 30 - December 1, 2022 | Boston, MA Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 